A patent was received for a group of inventions “Nanostructured composition for oral delivery of insulin and a method for its production” by a team of scientists from Lobachevsky University in Nizhny Novgorod, in the mid-Volga region.
The proposed group of inventions relates to medicine, pharmacology and biotechnology and can be used, for example, for the treatment of diabetes mellitus. Currently, chitosan-based nanoparticles are considered a promising means of oral insulin delivery. Scientists attribute its non-toxicity and safety to both animals and humans to the advantages of nanoparticles based on chitosan, obtained from shells of crustaceans and insects.
“Chitosan, available as an oral tablet, can reduce the intake of fat and cholesterol in the diet of a diabetic patient. In addition to protecting insulin from acid denaturation and enzymatic degradation, chitosnan-based nanoparticles have mucoadhesive properties, that is, the ability to adhere to the surface of mucous tissues in the human or animal body, thereby gradually releasing the active substance. Accordingly, the drug is better tolerated by the patient”, - the authors of the development note.
The task to be solved by the group of inventions is to obtain a method for oral delivery of insulin into the internal environment from the cavity of the gastrointestinal tract with subsequent prolonged the release of insulin from the drug into the blood is achieved.
The present group of inventions of scientists from UNN allows to increase the time of exposure to insulin, provides a prolonged decrease in blood glucose, increases safety and biocompatibility, and reduces toxicity.